Document Detail

Bortezomib Retreatment in Relapsed Multiple Myeloma - Results from a Retrospective Multicentre Survey in Germany and Switzerland.
MedLine Citation:
PMID:  21372599     Owner:  NLM     Status:  Publisher    
Objectives: This multicenter, retrospective survey evaluated the efficacy and safety of bortezomib retreatment in patients with relapsed multiple myeloma who had responded to initial bortezomib treatment. Methods: Clinical records of 94 patients receiving bortezomib retreatment in Germany and Switzerland were reviewed. Results: Sixty patients were included according to prespecified criteria. Patients had received a mean 3.7 ± 2.3 therapies prior to initial bortezomib. Overall response rate to bortezomib retreatment was 63.3%; 8 (13.3%), 3 (5.0%) and 27 (45.0%) patients achieved complete response (CR), near-CR and partial response, respectively. Response to retreatment was associated with response to initial treatment (75.0% of patients with CR to initial treatment responded to retreatment) and treatment-free interval (TFI) after initial treatment (76.9 vs. 38.1% overall response rate for patients with TFI >6 vs. ≤6 months). After retreatment, median time to progression was 9.3 months. Median TFI was 5.7 months; 31.7, 25.0 and 15.0% of patients experienced a TFI longer than 6, 9 and 12 months, respectively. Reported adverse drug reactions were consistent with the known safety profile of bortezomib and most resolved completely. Conclusions: These results demonstrate that relapsed multiple myeloma patients who respond to initial bortezomib treatment have a sustained susceptibility to bortezomib and do not experience uncommon toxicity to retreatment.
I Hrusovsky; B Emmerich; A von Rohr; J Voegeli; C Taverna; R A Olie; H Pliskat; C Frohn; G Hess
Related Documents :
9073699 - A prospective randomized trial comparing a gnrh analog, zoladex, and danazol as agents ...
21546269 - Levosimendan versus intra-aortic balloon pump in high-risk cardiac surgery patients.
21118739 - Ease of use and preference for a new disposable self-injection pen compared with a reus...
21242089 - Apical-access-related complications associated with trans-catheter aortic valve implant...
21085929 - Clinical and radiographic outcomes of minimally invasive total knee arthroplasty throug...
21256699 - Ten-year follow-up of avascular necrosis of femoral head treated with alendronate for 3...
11748439 - Renaissance of 224 ra for the treatment of ankylosing spondylitis: clinical experiences.
23010339 - A pilot randomised controlled trial in intensive care patients comparing 7 days' treatm...
23652849 - Endovascular treatment of brain arteriovenous malformations using a liquid embolic agen...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-3-03
Journal Detail:
Title:  Oncology     Volume:  79     ISSN:  1423-0232     ISO Abbreviation:  -     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-3-4     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0135054     Medline TA:  Oncology     Country:  -    
Other Details:
Languages:  ENG     Pagination:  247-254     Citation Subset:  -    
Copyright Information:
Copyright © 2011 S. Karger AG, Basel.
Diakonie-Krankenhaus, Schwäbisch Hall, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Functional and Clinicopathological Analysis of Loss of MKK4 Expression in Endometrial Cancer.
Next Document:  Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally adva...